E pEndymomas represent 6%-12% of all primary pediatric intracranial neoplasms and up to 30% of all primary brain tumors in children younger than 3 years. 13 Anaplastic ependymomas exhibit high mitotic activity often accompanied by microvascular proliferation and pseudopalisading necrosis, features that portend a poor response to treatment and survival. 13 The standard treatment for childhood intracranial ependymoma is resection followed by external beam fractionated RT. 9, 11, 21, 25 Even when complete resection was performed by Massimino et al., 17 the 5-year PFS was 32%. Survival improved to 52% after RT plus adjuvant chemotherapy. Unfortunately, complete resection is not always feasible. Residual or recurrent ependymomas are difficult to manage and require further surgery, chemotherapy, or additional RT. 6 Stereotactic radiosurgery has been used as an adjunct in the management of intracranial ependymoma and an effective modality for ependymomas that progress or recur after initial resection and postoperative RT. 2, 8, 10, 12, 13, 27 We reviewed our experience with 21 pediatric patients Object. To evaluate the role of stereotactic radiosurgery (SRS) in patients with recurrent or residual intracranial ependymomas after resection and fractionated radiation therapy (RT), the authors assessed overall survival, distant tumor relapse, progression-free survival (PFS), and complications.
who underwent SRS using the Leksell Gamma Knife. In an earlier study we reviewed outcomes in both adults and children, but in this report we focus on pediatric patients eligible for a longer follow-up. We evaluated tumor control, patient survival, AREs, and other variables that might affect treatment outcomes.
Methods
This retrospective study was approved by the University of Pittsburgh Institutional Review Board.
Patient Population
Between December 1989 and February 2008, 21 pediatric patients (younger than 18 years) with histologically confirmed ependymomas (WHO Grade II or III) underwent SRS for 32 tumors ( Table 1 ). The patients consisted of 17 boys and 4 girls with a median age of 6.9 years (range 2.9-17.2 years). All patients underwent an initial resection followed by fractionated RT (median tumor dose 52.2 Gy). Twelve patients had cranial radiation only, and 9 patients had neuraxis RT because spinal drop metastases were recognized at the time of staging after surgery. The median interval between the last excision (14 patients had > 1 resection) and SRS was 38.2 months (range 15.3-167 months). The median interval between RT and SRS was 36.7 months (range 6.7-167 months). Ten patients with recurrent tumors underwent initial GTR (6 had Grade II ependymomas and 4 had Grade III tumors). Eleven patients with residual tumors underwent initial STR (6 had Grade II and 5 had Grade III ependymomas). Eleven patients received chemotherapeutic agents that included Taxol, cisplatin, VP-16, vincristine, Cytoxan, carboplatin, and etoposide, alone or in combination. Twenty patients with 31 tumors underwent SRS at the time of tumor recurrence or progression as confirmed by serial imaging studies. The 
Radiosurgical Technique
Radiosurgery was performed with the Model U, B, C, or 4-C Leksell Gamma Knife (Elekta, Inc.). Our radiosurgical technique has been described in detail in previous reports. 13 The procedure began with the application of a Model G Leksell stereotactic frame with the patient under conscious sedation and local scalp anesthesia, unless the child was younger (usually younger than 12 years), in which case general anesthesia was used. After attaching a fiducial system to the frame, all patients underwent high-resolution MR imaging. A 3D localizer sequence, which included axial, coronal, and sagittal images, was performed first. The tumor was then visualized using 3D gradient-recalled sequences. Fast spin echo T2-weighted MR images were also acquired to assess the infiltrative tumor volume. In 32 tumors the SRS treatment volume was defined according to the enhancing tumor volume. In 1 patient who had a nonenhancing tumor, the radiosurgery treatment volume was based on the T2-weighted MR imaging volume.
The median tumor volume was 2. , respectively (p = 0.478, Mann-Whitney test). A median of 4 isocenters (range 1-13 isocenters) was used for dose planning. The median prescription dose delivered to the margins of the tumor was 15 Gy (range 9-22 Gy). The median doses to the tumor margins of Grades II and III ependymomas were 13.0 and 16.0 Gy, respectively (p = 0.008, MannWhitney test). Maximum doses varied from 18 to 40 Gy (median 30 Gy). All patients received an intravenous dose of 20-40 mg methylprednisolone after SRS, and all were discharged from the hospital within 24 hours of SRS.
All patients were evaluated with MR imaging at intervals of 3-6 months after radiosurgery. All living patients had a minimum of 6 months of follow-up. Nineteen patients had follow-up of 24 months or more. The mean and median follow-up times were 27.6 and 21.6 months, respectively (range 6.1-72.8 months). Follow-up MR images were compared with intraoperative images, and tumor dimensions were measured in the axial, sagittal, and coronal planes. A complete response was defined as the complete disappearance of enhancing or nonenhancing tumor, a partial response as > 50% shrinkage of the tumor volume, stable disease as a ≤ 25% change in tumor volume, and progressive disease as a > 25% increase in volume of the enhancing or nonenhancing tumor.
For statistical analysis we constructed Kaplan-Meier plots for OS and PFS using the dates of diagnosis, first SRS, follow-up MR images, and death or last follow-up. Progression-free survival and OS time were also calculated from the day of the first SRS by using the KaplanMeier method. Univariate analysis was performed on the Kaplan-Meier curves using a log-rank statistic, with p < 0.05 set as significant. Standard statistical processing software (SPSS, version 17.0, SPSS, Inc.) was used.
Results

Patient Survival
At the time of our analysis 9 patients (43%; 4 with Grade II and 5 with Grade III lesions) were alive at a mean follow-up of 27.6 months after SRS. Overall series survival after an initial diagnosis was 85.7%, 73.5%, and 43.3% at 3, 5, and 10 years, respectively (Fig. 1) . The median survival after initial diagnosis was 113.7 months (95% CI 50.62-176.75 months). The OS after SRS was 85.2%, 53.2%, and 23.0% at 1, 2, and 3 years, respectively. The median survival after SRS was 27.6 months (95% CI 19.33-35.87 months). Nine of 12 patients (8 with Grade II and 4 with Grade III tumors) died due to distant neuraxis tumor relapse, and 3 patients died due to local tumor progression.
Distant Tumor Relapse
Nine patients (43%) were found to have spinal metastases at the time of initial surgical staging, and all underwent neuraxis RT before SRS. Distant intracranial or spinal relapse after RT and SRS occurred in 6 (50%) of 12 patients with Grade II ependymomas and 4 (44%) of 9 patients with Grade III lesions. The distant tumor relapse rate after SRS was 33.6%, 41.0%, and 80.3% at 1, 2, and 3 years, respectively (Fig. 2) . The median interval until distant tumor relapse after SRS was 29.9 months (95% CI 2.58-57.22 months).
Local Tumor Control
Follow-up imaging studies demonstrated local tumor control in 23 (72%) of 32 tumors at the final follow-up (Table 2) . After radiosurgery, a complete response was identified in 4 treated tumors; all were Grade III lesions. A partial response was demonstrated in 9 treated tumors; 7 were Grade II and 2 were Grade III ependymomas. The appearance of 10 tumors remained unchanged after SRS; 7 were Grade II and 3 were Grade III ependymomas. Delayed tumor progression was detected in 9 treated tumors; 3 were Grade II and 6 were Grade III ependymomas.
Six patients required additional surgical procedures: 1 underwent surgical debulking alone, 2 had debulking followed by chemotherapy, and 3 patients underwent repeat SRS. Progression-free survival after the initial SRS was 78.4%, 55.5%, and 41.6% at 1, 2, and 3 years, respectively (Fig. 3) . The median PFS was 26.0 months (95% CI 9.40-42.60 months).
Statistical Analysis
We performed univariate analysis using the log-rank test to assess factors that influenced the duration of OS and PFS. The following variables were assessed: sex (boy vs girl), age (≥ 7 vs < 7 years), tumor grade (II vs III), prior chemotherapy (yes vs no), initial GTR (total vs partial), spinal dissemination (yes vs no), tumor location (posterior fossa/other locations vs fourth ventricle/other locations), radiosurgery target volume (≥ 2.2 vs < 2.2 cm 3 ), tumor margin dose (≥ 15 vs < 15 Gy), and interval between RT and SRS (≥ 18 vs < 18 months) ( Table 3 ).
An interval ≥ 18 months between RT and SRS was associated with a longer survival (p = 0.035). The WHO tumor grade did not correlate with survival. 
Adverse Radiation Effects
Adverse radiation effects were demonstrated on imaging in 2 patients (9.5%), but only 1 patient became symptomatic. One 3-year-old boy (Case 8) with a Grade II cerebellopontine angle ependymoma received an SRS dose of 12 Gy to the tumor margin, and an ipsilateral facial paresis developed 3 months after SRS. Magnetic resonance imaging showed increased peritumoral T2 signal changes. This patient was successfully treated with a short course of corticosteroids. An 8-year-old boy (Case 12) with a frontal lobe Grade II ependymoma had asymptomatic MR imaging evidence of increased contrast en- hancement with peritumoral T2 signal changes 6 months after SRS. This patient had received 15 Gy of radiation to the tumor margin.
Discussion
Options for the Management of Ependymomas
The standard treatment for pediatric patients with confirmed primary intracranial ependymomas is resection followed by RT. The extent of resection is associated with patient survival and local tumor control. 16, 20, 21, 25 Survival is significantly better after GTR as compared with STR. 29 In our series, 10 patients underwent initial total tumor resection and 11 underwent STR or partial resection. We were unable to glean from a review of the operative reports whether the responsible surgeon suspected microscopic residual disease at the time of reported GTR. Twenty of 21 patients had what was defined as delayed recurrence or progression of a tumor after the initial resection and RT. One patient underwent SRS for residual tumor in the early period after STR followed by RT. Radiation therapy doses of 45-54 Gy have been recommended in an effort to improve local control. 7, 9 When spinal spread is detected at the time of disease staging after the initial surgery, RT is often prescribed to the entire neuraxis.
Recurrent ependymomas are especially difficult to manage, and additional relapses requiring further surgery, radiation, or chemotherapy are common. 6 When tumors recur, chemotherapy has shown relatively little additional benefit. 22 In our small series, chemotherapy was not significantly associated with better OS, PFS, or reduced distant tumor relapse.
The literature does not clearly differentiate outcomes of ependymoma management based on tumor grading. 
Distant Tumor Relapse
Neuraxis dissemination has been reported to develop in approximately 10% of patients with primary intracranial ependymomas that have been surgically removed and then treated with RT. 3, 23 In our series, distant tumor relapse after RT and SRS occurred in 10 patients. The distant tumor relapse rate after RT and SRS was 33.6%, 41.0%, and 80.3% at 1, 2, and 3 years, respectively. Patients with spinal metastases before RT, tumors located in the 4th ventricle, and an RT to SRS interval < 18 months had a significantly greater chance of distant tumor relapse after SRS. We suspect that an earlier relapse after RT may portend a tumor that is biologically more aggressive. Several studies have suggested that younger patients also have worse survival rates.
9,16
Repeated Fractionated Radiation for Recurrent Ependymomas
Merchant et al. 18 reported that 3 of 13 patients treated using repeated focal fractionated radiation (median combined dose 111.6 Gy) experienced delayed neuraxis spread. Nineteen patients underwent craniospinal radiation treatment after failed initial RT. Four of 19 patients had metastatic spread, 2 had local failure, and 1 had combined failure. Liu et al. 15 reported that 6 pediatric patients with ependymomas underwent repeat RT after failed initial RT. All 6 patients were alive without evidence of disease at a median follow-up of 28 months. Three of 6 patients had evidence of radiation necrosis (1 was asymptomatic, whereas 2 had ataxia and headache), but all 3 patients did not require steroids and demonstrated improvement on imaging. Both repeat resection and repeat fractionated RT are additional treatment options for recurrent disease that has failed to respond to surgery and initial RT. The risk/benefit ratio of repeat surgery or RT in comparison with SRS is difficult to assess.
Stereotactic Radiosurgery as Adjuvant Management for Recurrent Ependymomas
Stereotactic radiosurgery has been used as adjuvant management for pediatric as well as adult ependymomas after a prior resection followed by RT. We found only scattered reports of SRS as an adjuvant management for pediatric ependymomas that progress or recur after prior surgical removal followed by RT. In our series only 9 (43%) of 21 pediatric patients with ependymomas were alive at a mean follow-up of 27.6 months (range 6.1-72.8 months). It is difficult to calculate the risk of late potential AREs, including secondary radiation-related malignancies, in this small series of patients in whom initial conventional management already failed. This concern would have greater traction if extended survivals in the context of recurrent ependymoma were possible. Longterm survivors of radiation in childhood remain at risk for the subsequent development of additional tumors such as meningiomas and other glial neoplasms. 19, 28, 31 Weprin et al. 30 reported on 3 patients with recurrent pediatric ependymomas treated using SRS, with 2 patients having poor outcomes. One patient survived, 1 died of disease progression, and 1 died of radiation necrosis. Hodgson et al. 10 described 28 patients with pediatric ependymomas who underwent SRS for residual or recurrent tumors after RT (median PFS was 8.5 months, and 3-year PFS was 29%). Merchant et al. 18 described 6 pediatric patients with ependymomas (4 had Grade II and 2 had Grade III tumors) treated with SRS for a recurrence after RT. The median dose to the tumor margin was 18 Gy (range 15-20 Gy). Two patients had local progression at 6 and 12 months and died, and 2 patients died of local and distant disease at 8 and 19 months. One patient died of radiation necrosis at 40 months. Only 1 patient had survived without a tumor recurrence at 10 years but did require surgery and hyperbaric O 2 therapy for AREs 8 years after SRS. Krieger and McComb 14 reported in their review article that SRS for patients with pediatric ependymomas might have significant benefits when used as a boost to RT at the time of initial treatment. It should be considered as an option in recurrent ependymomas that have failed to respond to up-front RT. In our series, an interval ≥ 18 months between RT and SRS was associated with longer survival (p = 0.035) and reduced distant tumor relapse (p = 0.015). We suspect that an early tumor relapse after RT may indicate a more biologically aggressive ependymoma or one less responsive to conventional fractionated RT. 
Conclusions
After failed prior surgery, RT, and possibly chemotherapy, SRS remains an additional strategy for progressive disease. Pediatric patients with small-volume ependymomas and a later recurrence responded best. A future study might be able to determine whether an earlier application of SRS after RT would reduce local recurrence and distant tumor relapse.
